Skip to main content
SpringerLink
Log in

Management des Endometriumkarzinoms

Standards und neue Trends

  • Weiterbildung · Zertifizierte Fortbildung
  • Published:
Der Gynäkologe Aims and scope

Zusammenfassung

Das Endometriumkarzinom ist in Industriestaaten nach dem Brustkrebs das häufigste gynäkologische Malignom der Frau. Die Operation stellt sowohl aus diagnostischer (Staging) als auch therapeutischer Sicht (Wahl der Anschlusstherapie) die wichtigste Maßnahme im Management des Endometriumkarzinoms dar. Verschiedene Aspekte in der operativen und adjuvanten Behandlung haben sich im klinischen Alltag durchgesetzt, ohne dass der Nutzen jedoch durch valide Studienergebnisse belegt wurde. Hierzu zählen u. a. die Wertheim-Meigs-Operation im Stadium II und der breite Einsatz der adjuvanten Radiatio. In der vorliegenden Arbeit werden die risikoadaptierten Therapieempfehlungen kritisch diskutiert und neue Trends in der Behandlung des Endometriumkarzinoms aufgezeigt.

Abstract

Cancer of the endometrium is the second most common gynecologic cancer among women in western countries. Primary surgery is the most important procedure in diagnosis (staging) and therapy (selection criteria for adjuvant treatment) in the management of endometrial cancer. Despite lacking data in the literature different aspects of surgical technique and adjuvant therapy are part of the clinical routine. For instance, although intracavitary and external-beam irradiation have been used to treat endometrial carcinomas for almost a century, the influence of adjuvant irradiation on the survival rate of patients with endometrial carcinomas has never been clearly determined. There is also not one prospective randomised trial which has demonstrated the benefit of a radical hysterectomy in stage II. This article dicusses the risk-based treatment recommendations and presents new trends in the therapy of endometrial cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Aalders J, Abeler V, Kolstad P, Onsrud M (1987) Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: Clinical and histopathologic study of 540 patients. Obstet Gynecol 56: 419–427

    Google Scholar 

  2. Announcements (1989) FIGO stages: 1988 revision. Gynecol Oncol 35: 125–126

    Google Scholar 

  3. Barakat RR (2002) Contemporary management of endometrial cancer. Am Soc Clin Oncol Educational Book, pp 85–88

  4. Bauknecht T (1999) Prognosefaktoren beim Endometriumkarzinom. Onkologe 5: 396–402

    Article  Google Scholar 

  5. Boronow RC, Morrow CP, Creasman WT et al. (1984) Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol 63: 825

    CAS  PubMed  Google Scholar 

  6. Bremond A, Bataillard A, Thomas L et al. (2001) Standards, options and recommendations for the surgical management of carcinoma of the endometrium. Bull Cancer 88: 181–198

    CAS  PubMed  Google Scholar 

  7. Clark TJ, Voit D, Gupta JK, Hyde C, Song F, Khan KS (2002) Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia: a systematic quantitative review. JAMA 288: 1610–1621

    Article  PubMed  Google Scholar 

  8. Chuang L, Burke TW, Tornos C et al. (1995) Staging laparotomy for endomterial carcinoma: Assesment of retroperitoneal lymph nodes. Gynecol Oncol 58: 189–193

    Article  CAS  PubMed  Google Scholar 

  9. COSA-NZ-UK Endometrial Cancer Study Groups (1996) Pelvic lymphadenectomy in high risk endometrial cancer. Int J Gynecol Cancer 6: 102–107

    Article  Google Scholar 

  10. Creasman WT, Morrow CP, Bundy BN et al. (1987) Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 60 (Suppl): 2035–2041

    CAS  PubMed  Google Scholar 

  11. Emons G (2002) Endometriumkarzinom. In: Sehouli J, Lichtenegger W (Hrsg) Update 2002/03. Chemotherapien in der Gynäkologischen Onkologie. Akademos

  12. Emons G, Fleckenstein G, Hinney B, Huschmand A, Heyl W (2000) Hormonal interactions in endometrial cancer. Endocr Relat Cancer 7: 227–242

    PubMed  Google Scholar 

  13. Fanning J, Evans MC, Peters AJ et al. (1989) Endometrial adenocarcinoma histologic subtypes: clinical and pathologic profile. Gynecol Oncol 32: 288

    CAS  PubMed  Google Scholar 

  14. Fleming G F, Brunetto LV, Burks RT et al. (2002) Randomized trial of doxorubicin (DOX) plus cisplatin (CIS) versus DOX plus CIS plus paclitaxel (TAX) in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group (GOG) study. Proceedings of ASCO Abstract 807

  15. Gupta JK, Chien PF, Voit D, Clark TJ, Khan KS (2002) Ultrasonographic endometrial thickness for diagnosing endometrial pathology in women with postmenopausal bleeding: a meta-analysis. Acta Obstet Gynecol Scand 81: 799–816

    Article  PubMed  Google Scholar 

  16. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R (1982) Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 6: 93–108

    CAS  PubMed  Google Scholar 

  17. Hoskins P, Swenerton K, Pike J, Wong F, Lim P, Aquino-Parsons C, Lee N (2001) Carboplatin/paclitaxel irradiation for advanced or recurrent endometrial cancer. Proceedings of ASCO Abstract 820

  18. Deutsche Krebsgesellschaft, Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (2000) Interdisziplinäre kurzgefasste Leitlinien der Deutschen Krebsgesellschaft und der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe. Endometriumkarzinom. Kurzgefasste Interdisziplinäre Leitlinien B22, S 287

  19. Kaaks R, Lukanova A, Kurzer MS (2002) Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 11: 1531–1543

    CAS  PubMed  Google Scholar 

  20. Kilgore LC, Partridge EE, Alvarez RD, Austin JM, Shingleton HM, Noojin F, Conner W (1995) Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 56: 29–33

    Article  CAS  PubMed  Google Scholar 

  21. Kindermann G (1981) Zur Therapie des Endometriumkarzinoms. Geburtsh Frauenheilkd 41: 650

    Google Scholar 

  22. Larson DM, Broste SK, Krawisz BR (1998) Surgery without radiotherapy for primary treatment of endometrial cancer. Obstet Gynecol 91: 335

    Article  Google Scholar 

  23. Maggino T, Romagnolo C, Landoni F, Sartori E, Zola P, Gadducci A (1998) An analysis of approaches to the management of endometrial cancer in North America: a CTF study. Gynecol Oncol 68: 274–279

    Article  CAS  PubMed  Google Scholar 

  24. Maggino T, Romagnolo C, Zola P, Sartori E, Landoni F, Gadducci A (1995) An analysis of approaches to the treatment of endometrial cancer in western Europe: a CTF study. Eur J Cancer 31: 1993–1997

    Article  Google Scholar 

  25. Mariani A, Webb MJ, Keeney GL, Podratz KC (2001) Routes of lymphatic spread: a study of 112 consecutive patients with endometrial cancer. Gynecol Oncol 81: 100–104

    Article  CAS  PubMed  Google Scholar 

  26. Martin-Hirsch P L, Jarvis G, Kitchener H, Lilford R (2002) Progestagens for endometrial cancer (Cochrane Review). Cochrane Library 3

  27. Maugeri G, Nardo LG, Campione C, Nardo F (2001) Endometrial lesions after tamoxifen therapy in breast cancer women. Breast J 7: 240–244

    Article  CAS  PubMed  Google Scholar 

  28. Obermair A, Geramou M, Gucer F et al. (1999) Endometrial cancer: accuracy of the finding of a well differentiated tumor at dilatation and curettage compared to the findings at subsequent hysterectomy. Int J Gynecol Cancer 9: 383–386

    Article  PubMed  Google Scholar 

  29. Pecorelli S (1998) FIGO annual report on the result of treatment in gynaecological cancer, 23rd edn. J Epidemiol Biostat 3: 1-168

    Google Scholar 

  30. Podratz KC, Mariani A, Webb MJ (1998) Staging and therapeutic value of lymphadenectomy in endometrial cancer. Gynecol Oncol 70: 163–164

    Article  CAS  PubMed  Google Scholar 

  31. Randall ME, Brunetto G, Muss H et al. (2003) whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: a randomized phase III trial of the Gynecologic Oncology Group. Proceedings of ASCO Abstract 3

  32. Rose PG, Cha SD, Tak WK (1992) Radiation therapy for surgically proven paraaortic node metastasis in endometral carcinoma. Int Radiat Oncol Biol Phys 24: 229–233

    CAS  Google Scholar 

  33. Robert JA, Brunetto VL, Keys HM (1998) A phase III randomised study of surgery vs surgery plus adjuvant radiation in intermediate-risk endometrial adenocarcinoma (GOG no.99). Gynecol Oncol 68: 135

    Google Scholar 

  34. Robert-Koch-Institut (2003) Schätzung der Krebsneuerkrankungen in Deutschland.http://www.rki.de/GBE/KREBS/KREBS.HTM

  35. Sherman ME (2000) Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 13: 295–308

    CAS  PubMed  Google Scholar 

  36. Schmidt T, Romer T (2002) Sonography and hysteroscopy for endometrial carcinoma and its precursors. Zentralbl Gynakol 124: 20–26

    CAS  PubMed  Google Scholar 

  37. Sehouli Ji, Camara O, Stengel D, Köhler G, Lichtenegger W (2003) Multizentrische Umfrage zum Stellenwert der Lymphonodektomie beim Endometriumkarzinom in Deutschland. Gynäkol Geburtshilf Rundschau 43: 104–110

  38. Tamussino KF, Reich O, Gucer F, Moser F, Zivkovic F, Lang PF, Winter R (2000) Parametrial spread in patients with endometrial carcinoma undergoing radical hysterectomy. Int J Gynecol Cancer 10: 313–317

    Article  PubMed  Google Scholar 

  39. Thigpen JT, Blessing JA, DiSaia PJ, Yordan E, Carson LF, Evers C (1994) A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 12: 1408–1414

    CAS  PubMed  Google Scholar 

  40. Trimble EL, Kosary C, Park RC (1998) Lymph node sampling and survival in endometrial cancer. Gynecol Oncol 71: 340–343

    Article  CAS  PubMed  Google Scholar 

  41. Weidemann H, Hieronimus-Reichel A, Sehouli J et al. (2003) Multivisceral surgery for advanced gynaecological malignancies. Eur Surg 35: 102–105

    Google Scholar 

Download references

Interessenkonflikt:

Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.

Author information

Authors and Affiliations

  1. Klinik für Frauenheilkunde und Geburtshilfe, Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin

    J. Sehouli &  W. Lichtenegger

  2. Klinik für Frauenheilkunde und Geburtshilfe, Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13355, Berlin

    W. Lichtenegger

Authors
  1. J. Sehouli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Lichtenegger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W. Lichtenegger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sehouli, J., Lichtenegger, W. Management des Endometriumkarzinoms. Gynäkologe 37, 245–256 (2004). https://doi.org/10.1007/s00129-004-1497-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00129-004-1497-8

Schlüsselwörter

Keywords

Search

Navigation